Table 2 Clinical characteristics according to baseline eGFR
From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
Patient | Group H 6 (15%) | Group M 26 (65%) | Group L 8 (20%) | p-value |
|---|---|---|---|---|
[background factors] | ||||
 Age, median [range] | 53.5 [40–70] | 66.5 [33–78] | 73 [67–78] | 0.0055 |
 Sex, male (%) | 0 (0) | 8 (30.8) | 5 (62.5) | 0.0206 |
 BW (kg), median [range] | 50.5 [41.6–61] | 58.0 [38.5–97.1] | 61.5 [35.3–79.2] | 0.1810 |
 Histopathology, follicular (%) | 3 (50.0) | 8 (30.8) | 4 (50.0) | 0.4916 |
 Performance status, ≥ 1 | 3 (50.0) | 11 (42.3) | 3 (37.5) | 0.8959 |
 eGFR at baseline (mL/min/1.73 m2), median [range] | 104.5 [92.8–119.1] | 73.3 [60.4–88.7] | 49.9 [43.6–58.3] | < 0.0001 |
 Proteinuria grade 1 at baseline, yes (%) | 0 (0) | 2 (7.7) | 0 (0) | 0.4108 |
 Past hypertension history (%) | 1 (16.7) | 16 (61.5) | 7 (87.5) | 0.0207 |
 Past diabetes mellitus history (%) | 1 (16.7) | 1 (3.9) | 1 (12.5) | 0.4970 |
 Past renal history (%) | 0 (0) | 3 (11.5) | 0 (0) | 0.2574 |
 Renal metastasis, (%) | 0 (0) | 3 (11.5) | 0 (0) | 0.4108 |
 Liver metastasis, (%) | 0 (0) | 6 (23.1) | 1 (12.5) | 0.2255 |
[treatment factors] | ||||
 Treatment period (months), [average] | 38.1 ± 16.3 | 31.3 ± 16.8 | 29.1 ± 17.7 | 0.5434 |
 Observation period (months), [average] | 46.2 ± 11.8 | 31.8 ± 15.2 | 25.7 ± 15.0 | 0.0431 |
 Dose Intensity, median [average] | 10.2 ± 2.0 | 9.4 ± 3.0 | 10.4 ± 3.5 | 0.6515 |
 Best response in RECIST criteria, PR (%) | 6 (100) | 20 (77) | 3 (38) | 0.0463 |
 Proteinuria grade 3, yes (%) | 5 (83) | 14 (54) | 2 (25) | 0.0914 |
 Treatment continuation, yes (%) | 3 (50) | 10 (38) | 4 (50) | 0.7812 |
 Treatment termination due to renal problem *, yes (%) | 1 (17) | 5 (19) | 1 (13) | 0.9020 |